Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

NCT05910177 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER_GOV

Sponsor class

Conditions

Carcinoma
Cervix Carcinoma

Interventions

DRUG: Karelizumab combined with etoposide and cisplatin

Sponsor

Fujian Cancer Hospital